Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of "Hold" by Analysts

Key Points

• Alto Neuroscience, Inc. has received a consensus rating of "Hold" from nine analysts, with one sell recommendation, three holds, and five buys.
• The company's average 12-month target price is $9.80, significantly lower than the recent price targets from some brokerages, which include a $15.00 price target from Chardan Capital.
• Recently, Alto Neuroscience reported a quarterly loss of ($0.65) EPS, missing analysts' expectations, while institutional investors have been increasing their stakes in the company.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has earned an average rating of "Hold" from the nine brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $9.80.

ANRO has been the topic of a number of recent research reports. Chardan Capital initiated coverage on shares of Alto Neuroscience in a research note on Monday, September 29th. They set a "buy" rating and a $15.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Alto Neuroscience in a research note on Monday, August 18th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a research note on Saturday, September 27th.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $6.55 on Tuesday. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $15.04. The company has a 50-day simple moving average of $3.74 and a 200 day simple moving average of $2.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43. The company has a market capitalization of $177.35 million, a PE ratio of -2.74 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08). On average, research analysts predict that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

A number of institutional investors have recently modified their holdings of ANRO. Armistice Capital LLC lifted its stake in shares of Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company's stock valued at $3,456,000 after buying an additional 950,000 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in Alto Neuroscience during the second quarter valued at approximately $613,000. AWM Investment Company Inc. grew its stake in Alto Neuroscience by 31.1% during the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company's stock valued at $1,948,000 after acquiring an additional 214,153 shares in the last quarter. Nuveen LLC purchased a new position in Alto Neuroscience during the first quarter valued at approximately $302,000. Finally, Jane Street Group LLC purchased a new position in Alto Neuroscience during the second quarter valued at approximately $240,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.